Delcath Systems secures up to $85M financing led by Vivo Capital, $25M upfront

DELCATH SYSTEMS, INC.

Financing includes $24.9M in Series F Convertible Preferred and two warrant tranches totaling $59.8M.
Tranche A warrants ($34.9M) exercisable until 3/31/2026 or 21 days after FDA approval of HEPZATO.
Tranche B warrants ($24.9M) exercisable until 3/31/2026 or 21 days after $10M quarterly HEPZATO revenue.
Conversion and exercise require stockholder approval; funding expected to cover through PDUFA date of Aug 14, 2023 and commercialization.
Participants include Vivo Capital, Logos Capital, BVF Partners, Stonepine Capital, Serrado Capital, and existing investor Rosalind Advisors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

DELCATH SYSTEMS, INC. reported financial results for the fiscal quarter and year ended December 31, 2022.

Period: the fiscal quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 27, 2023, Delcath Systems, Inc. (the “Company”) issued a press release, furnished as Exhibit 99.1 and incorporated in this Item 2.02 by reference, announcing its financial results for the fiscal quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

DELCATH SYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-080510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.